LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

Search

Ligand Pharmaceuticals Inc

Open

BrancheGesundheitswesen

200.75 -2.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

196.45

Max

207.35

Schlüsselkennzahlen

By Trading Economics

Einkommen

47M

4.8M

Verkäufe

70M

115M

KGV

Branchendurchschnitt

92.606

105.69

Gewinnspanne

4.198

Angestellte

68

EBITDA

103M

62M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+18.65% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.5B

4.1B

Vorheriger Eröffnungskurs

202.94

Vorheriger Schlusskurs

200.75

Nachrichtenstimmung

By Acuity

28%

72%

70 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Nov. 2025, 18:59 UTC

Wichtige Markttreiber

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. Nov. 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. Nov. 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. Nov. 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. Nov. 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. Nov. 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q Rev $2.6B >TCOM

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. Nov. 2025, 22:02 UTC

Ergebnisse

Trip.com Group 3Q EPS $4.02 >TCOM

17. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Nov. 2025, 21:40 UTC

Ergebnisse

James Hardie Industries 2Q Adj EPS 26c >JHX

17. Nov. 2025, 21:40 UTC

Ergebnisse

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. Nov. 2025, 21:39 UTC

Ergebnisse

James Hardie Industries 2Q Sales $1.29B >JHX

17. Nov. 2025, 21:38 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 21:38 UTC

Ergebnisse

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. Nov. 2025, 21:10 UTC

Ergebnisse

XP Inc. 3Q EPS BRL2.47 >XP

17. Nov. 2025, 21:10 UTC

Ergebnisse

XP Inc. 3Q Rev BRL4.67B >XP

17. Nov. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. Nov. 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. Nov. 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Nov. 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. Nov. 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. Nov. 2025, 19:16 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. Nov. 2025, 16:45 UTC

Akquisitionen, Fusionen, Übernahmen

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. Nov. 2025, 16:16 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. Nov. 2025, 16:15 UTC

Ergebnisse

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. Nov. 2025, 15:40 UTC

Akquisitionen, Fusionen, Übernahmen

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. Nov. 2025, 15:22 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. Nov. 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer-Vergleich

Kursveränderung

Ligand Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

18.65% Vorteil

12-Monats-Prognose

Durchschnitt 238.33 USD  18.65%

Hoch 275 USD

Tief 220 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ligand Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

102.5 / 109.24Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

70 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat